RGD-FasL induces apoptosis of pituitary adenoma cells

Cellular and Molecular Immunology

Volumn 5, Issue 1, 2008, Pages 61-68

  Chen, Lukui ^a   Zhuang, Guohong ^a   Li, Wenzhu ^a   Liu, Yunsheng ^b   Zhang, Junqing ^a   Tian, Xinhua ^a  

^a XIAMEN UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

apoptosis; pituitary adenoma; RGD FasL

Indexed keywords

ARGINYL-GLYCYL-ASPARTIC ACID; ARGINYLGLYCYLASPARTIC ACID; CASPASE; DECOY RECEPTOR 3; FAS ANTIGEN; FAS LIGAND; MITOGEN ACTIVATED PROTEIN KINASE 9; OLIGOPEPTIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEIN BCL 2; TNFRSF6B PROTEIN, HUMAN; TNFSF11 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE; HUMAN; HYPOPHYSIS TUMOR; IMMUNOLOGY; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANTIGENS, CD95; APOPTOSIS; CASPASES; CELL CYCLE; CELL LINE, TUMOR; FAS LIGAND PROTEIN; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 9; OLIGOPEPTIDES; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RANK LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 6B;

EID: 47049126967     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2008.8     Document Type: Article

References (39)

1. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer. 2002;2:836-849. (Pubitemid 37328902)
2. Norbury CJ, Zhivotovsky B. DNA damage-induced apoptosis. Oncogene. 2004;23:2797-2808. (Pubitemid 38638843)
3. Randall RV, Laws ER Jr, Abboud CF, Ebersold MJ, Kao PC, Scheithauer BW. Transsphenoidal microsurgical treatment of prolactin-producing pituitary adenomas: Results in 100 patients. Mayo Clin Proc. 1983;58:108-121.
4. Wilson CB. A decade of pituitary microsurgery: The Herbert Olivecrona Lecture. J Neurosurg. 1984;61:814-833. (Pubitemid 15203732)
5. Laws ER Jr, Scheithauer BW, Carpenter S, Randall RV, Abboud CF. The pathogenesis of acromegaly: clinical and immunocytochemical analysis in 75 patients. J Neurosurg. 1985;63:35-38. (Pubitemid 15067269)
6. Liu YQ, Mu ZQ, You S, Tashiro S, Onodera S, Ikejima T. Fas/FasL signaling allows extracelluar-signal regulated kinase to regulate cytochrome c release in oridonin-induced apoptotic U937 cells. Bio Pharm Bull. 2006;29:1873-1879. (Pubitemid 44338410)
7. Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J Biol Chem. 1999;274:22532-22538.
8. Chen G, Goeddel DV. TNF-R1 signaling: a beautiful pathway. Science. 2002;296:1634-1635. (Pubitemid 34579145)
9. Gonzalvez F, Pariselli F, Dupaigne P, et al. tBid interaction with cardiolipin primarily orchestrates mitochondrial dysfunctions and subsequently activates Bax and Bak. Cell Death Differ. 2005;12:614-626. (Pubitemid 40767164)
10. Cecconii F. Apaf1 and the apoptotic machinery. Cell Death Differ. 1999;6:1087-1098.
11. Degterev A, Boyce M, Yuan J. A decade of caspases. Oncogene. 2003;22:8543-8567. (Pubitemid 38028527)
12. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365. (Pubitemid 27131377)
13. Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science. 1998;281:1305-1308. (Pubitemid 28406815)
14. Qin J, Chen D, Hu H, Qiao M, Zhao X, Chen B. Body distributioin of RGD-mediated liposome in brain-targeting drug delivery. Yakugaku Zasshi. 2007;127:1497-1501. (Pubitemid 47360748)
15. Villard V, Kalvuzhniv O, Riccio O, et al. Synthetic RGDcontaining α-helical coiled coil peptides promote integrindependent cell adhesion. J Pept Sci. 2006;12:206-212. (Pubitemid 43349361)
16. Wu PL, Lee SC, Chuang CC, et al. Non-cytotoxic cobra cardiotoxin A5 binds to αvβ3 integrin and inhibits bone resorption. Identification of cardiotoxins as non-RGD integrinbinding proteins of the Ly-6 family. J Bio Chem. 2006;281: 7937-7945.
17. Lu X, Lu D, Scully MF, Kakkar VV. Integrins in drug targeting-RGD templates in toxins. Curr Pharm Des. 2006;12: 2749-2769. (Pubitemid 44184634)
18. Candolfi M, Zaldivar V, De Laurentiis A, Jaita G, Pisera D, Seilicovich A. TNF-α induces apoptosis of lactotropes from female rats. Endocrinology. 2002;143:3611-3617. (Pubitemid 34925738)
19. Candolfi M, Jaita G, Zaldivar V, Zarate S, Pisera D, Seilicovich A. Tumor necrosis factor-α-induced nitric oxide restrains the apoptotic response of anterior pituitary cells. Neuroendocrinology. 2004;80:83-91. (Pubitemid 39664077)
20. Candolfi M, Jaita G, Zaldivar V, et al. Progesterone antagonizes the permissive action of estradiol on tumor necrosis factor-α- induced apoptosis of anterior pituitary cells. Endocrinology. 2005;146:736-743. (Pubitemid 40129829)
21. Jaita G, Candolfi M, Zaldivar V, et al. Estrogens up-regulate the Fas/FasL apoptotic pathway in lactotropes. Endocrinology. 2005; 146:4737-4744. (Pubitemid 41446611)
22. Los M, Voest EE. The potential role of antivascular therapy in the adjuvant and neoadjuvant treatment of cancer. Semin Oncol. 2001;28:93-105. (Pubitemid 32172412)
23. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Metastasis Rev. 1990;9:267-282. (Pubitemid 20380383)
24. Baillie CT, Winslet MC, Bradley NJ. Tumor vasculature-a potential therapeutic target. Br J Cancer. 1995;72:257-267.
25. Ruoslahti E. Specialization of tumor vasculature. Nat Rev Cancer. 2002;2:83-90.
26. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 1998;279:377-380. (Pubitemid 28063372)
27. Brooks PC, Clark RAF, Cheresh DA. Requirement of vascular integrin αVβ3 for angiogenesis. Science. 1994;264:569-571.
28. Ruoslahti E. RGD and other recognition sequences for integrins. Annu Rev Cell Dev Biol. 1996;12:697-715. (Pubitemid 26422728)
29. Cleaver O, Melton DA. Endothelial signaling during development. Nat Med. 2003;9:661-668. (Pubitemid 36749214)
30. Pasqualini R, Koivunen E, Ruoslahti E. αβ integrins as receptors for tumor targeting by circulating ligands. Nat Biotech. 1997;15:542-546. (Pubitemid 27251571)
31. Kobayashi H, Fukata J, Murakami N, et al. Tumor necrosis factor receptors in the pituitary cells. Brain Res. 1997;758:45-50. (Pubitemid 27310641)
32. Huang P, Tofighi R, Emgard M, Ceccatelli S. Cell death induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin (2,3,7,8-TCDD) in AtT-20 pituitary cells. Toxicology. 2005;207:391-399. (Pubitemid 40138936)
33. Bianco SR, Sun J, Fosmire SP, et al. Enhancing antimelanoma immune responses through apoptosis. Cancer Gene Ther. 2003; 10:726-736. (Pubitemid 37129460)
34. Nakanishi H, Mazda O, Satoh E, et al. Nonviral genetic transfer of Fas ligand induced significant growth suppression and apoptotic tumor cell death in prostate cancer in vivo. Gene Ther. 2003;10:434-442. (Pubitemid 36372451)
35. Rubinchik S, Yu H, Woraratanadharm J, Voelkel-Johnson C, Norris JS, Dong JY. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003;10:814-822. (Pubitemid 37414112)
36. Sanlioglu AD, Aydin C, Bozcuk H, Terzioglu E, Sanlioglu S. Fundamental principels of tumor necrosis factor-α gene therapy approach and implications for patients with lung carcinoma. Lung Cancer. 2004;44:199-211. (Pubitemid 38482053)
37. Pitti R, Marsters SA, Lawrence DA, et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature. 1998;396:699-703. (Pubitemid 29003951)
38. Lawen A. Apoptosis-an introduction. Bioessays. 2003;25:888-896.
39. Kang TB, Ben-Moshe T, Varfolomeev EE, et al. Caspase-8 serves both apoptotic and nonapoptotic roles. J Immunol. 2004; 173:2976-2984. (Pubitemid 39142002)